Handelsinvest Investeringsforvaltning boosted its stake in Johnson & Johnson (NYSE:JNJ) by 15.7% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 5,640 shares of the company’s stock after acquiring an additional 765 shares during the quarter. Handelsinvest Investeringsforvaltning’s holdings in Johnson & Johnson were worth $728,000 as of its most recent SEC filing.
Other institutional investors and hedge funds also recently bought and sold shares of the company. Carlson Capital Management increased its stake in Johnson & Johnson by 14.6% in the 4th quarter. Carlson Capital Management now owns 9,102 shares of the company’s stock valued at $1,175,000 after buying an additional 1,161 shares during the last quarter. Regent Investment Management LLC increased its stake in Johnson & Johnson by 3.1% in the 4th quarter. Regent Investment Management LLC now owns 53,048 shares of the company’s stock valued at $6,846,000 after buying an additional 1,608 shares during the last quarter. Landsberg Bennett & Dubbaneh LLC acquired a new stake in Johnson & Johnson in the 4th quarter valued at $752,000. Truewealth LLC increased its stake in Johnson & Johnson by 3.6% in the 4th quarter. Truewealth LLC now owns 8,147 shares of the company’s stock valued at $1,051,000 after buying an additional 282 shares during the last quarter. Finally, Gagnon Securities LLC increased its stake in Johnson & Johnson by 2.4% in the 4th quarter. Gagnon Securities LLC now owns 5,543 shares of the company’s stock valued at $715,000 after buying an additional 129 shares during the last quarter. 67.32% of the stock is currently owned by institutional investors and hedge funds.
Several brokerages have issued reports on JNJ. Zacks Investment Research upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating and set a $155.00 price target on the stock in a research note on Wednesday, March 27th. BMO Capital Markets lifted their price target on shares of Johnson & Johnson from $154.00 to $157.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $134.00 to $145.00 and gave the company an “equal weight” rating in a research note on Wednesday, April 17th. Raymond James lifted their price target on shares of Johnson & Johnson from $145.00 to $147.00 and gave the company an “outperform” rating in a research note on Wednesday, April 17th. Finally, Citigroup lifted their price target on shares of Johnson & Johnson from $139.00 to $147.00 and gave the company a “neutral” rating in a research note on Monday, February 25th. Five research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average price target of $146.40.
Johnson & Johnson stock opened at $137.52 on Monday. The stock has a market cap of $368.95 billion, a PE ratio of 16.81, a PEG ratio of 2.38 and a beta of 0.68. Johnson & Johnson has a fifty-two week low of $118.62 and a fifty-two week high of $148.99. The company has a current ratio of 1.47, a quick ratio of 1.20 and a debt-to-equity ratio of 0.46.
Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 16th. The company reported $2.10 earnings per share for the quarter, topping the consensus estimate of $2.03 by $0.07. The company had revenue of $20.02 billion for the quarter, compared to analyst estimates of $19.55 billion. Johnson & Johnson had a net margin of 17.99% and a return on equity of 35.79%. Johnson & Johnson’s revenue for the quarter was up .1% compared to the same quarter last year. During the same period in the previous year, the business earned $2.06 EPS. Research analysts expect that Johnson & Johnson will post 8.6 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: This report was originally posted by Highlight Press and is the sole property of of Highlight Press. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://highlightpress.com/2019/04/22/handelsinvest-investeringsforvaltning-boosts-position-in-johnson-johnson-jnj.html.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
Featured Story: What is the price-sales ratio?
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.